NO20032861L - Heteroarylurea nevropeptid Y Y5-reseptorantagonister - Google Patents

Heteroarylurea nevropeptid Y Y5-reseptorantagonister

Info

Publication number: NO20032861L
Authority: NO; Norway
Prior art keywords: heterory; receptor antagonists; neuropeptide; urea; urea neuropeptide
Prior art date: 2000-12-21

Application number

NO20032861A

Other languages

English (en)

Norwegian (no)

Other versions

NO20032861D0 (no

Inventor

Andrew W Stamford

Youhao Dong

Stuart W Mccombie

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-21

Filing date

2003-06-20

Publication date

2003-08-21

2003-06-20 Application filed by Schering Corp filed Critical Schering Corp

2003-06-20 Publication of NO20032861D0 publication Critical patent/NO20032861D0/no

2003-08-21 Publication of NO20032861L publication Critical patent/NO20032861L/no

Links

101710151321 Melanostatin Proteins 0.000 title 1
102400000064 Neuropeptide Y Human genes 0.000 title 1
102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 title 1
101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 title 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
239000004202 carbamide Substances 0.000 title 1
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1
208000030814 Eating disease Diseases 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
206010020710 Hyperphagia Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20032861A 2000-12-21 2003-06-20 Heteroarylurea nevropeptid Y Y5-reseptorantagonister NO20032861L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25730800P	2000-12-21	2000-12-21
PCT/US2001/049302 WO2002049648A1 (en)	2000-12-21	2001-12-17	Heteroaryl urea neuropeptide y y5 receptor antagonists

Publications (2)

Publication Number	Publication Date
NO20032861D0 NO20032861D0 (no)	2003-06-20
NO20032861L true NO20032861L (no)	2003-08-21

Family

ID=22975741

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032861A NO20032861L (no)	2000-12-21	2003-06-20	Heteroarylurea nevropeptid Y Y5-reseptorantagonister

Country Status (22)

Country	Link
US (1)	US6982267B2 (de)
EP (1)	EP1343503B1 (de)
JP (1)	JP4226326B2 (de)
KR (1)	KR20030061458A (de)
CN (2)	CN1807426A (de)
AR (1)	AR035520A1 (de)
AT (1)	ATE413880T1 (de)
AU (2)	AU3405602A (de)
BR (1)	BR0116379A (de)
CA (1)	CA2432809C (de)
DE (1)	DE60136562D1 (de)
ES (1)	ES2316486T3 (de)
HK (1)	HK1054333A1 (de)
HU (1)	HUP0303339A3 (de)
IL (1)	IL156157A0 (de)
MX (1)	MXPA03005745A (de)
NO (1)	NO20032861L (de)
NZ (1)	NZ526174A (de)
PE (1)	PE20020761A1 (de)
SG (1)	SG138463A1 (de)
WO (1)	WO2002049648A1 (de)
ZA (1)	ZA200304348B (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6946476B2 (en) *	2000-12-21	2005-09-20	Schering Corporation	Heteroaryl urea neuropeptide Y Y5 receptor antagonists
WO2003015717A2 (en) *	2001-08-17	2003-02-27	Merck & Co., Inc.	Tyrosine kinase inhibitors
US6673829B2 (en)	2001-09-14	2004-01-06	Novo Nordisk A/S	Aminoazetidine,-pyrrolidine and -piperidine derivatives
EP1430027B1 (de) *	2001-09-14	2010-09-01	High Point Pharmaceuticals, LLC	Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
ATE486842T1 (de)	2002-03-12	2010-11-15	Merck Sharp & Dohme	Substituierte amide
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
CA2490470A1 (en) *	2002-07-02	2004-01-15	Schering Corporation	Pyrazole urea neuropeptide y y5 receptor antagonists
AU2003267728A1 (en) *	2002-10-18	2004-05-04	Pfizer Products Inc.	Cannabinoid receptor ligands and uses thereof
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
JP4765627B2 (ja)	2003-09-22	2011-09-07	Ｍｓｄ株式会社	新規ピペリジン誘導体
JPWO2005040135A1 (ja) *	2003-10-24	2007-03-08	小野薬品工業株式会社	抗ストレス薬およびその医薬用途
US7291744B2 (en)	2003-11-13	2007-11-06	Bristol-Myers Squibb Company	N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
TW200630337A (en)	2004-10-14	2006-09-01	Euro Celtique Sa	Piperidinyl compounds and the use thereof
ES2325773T5 (es)	2004-11-01	2014-02-24	Amylin Pharmaceuticals, Llc.	Tratamiento de la obesidad y de los trastornos relacionados
WO2006060461A1 (en)	2004-12-03	2006-06-08	Schering Corporation	Substituted piperazines as cb1 antagonists
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
US8138206B2 (en)	2005-05-30	2012-03-20	Msd. K.K.	Piperidine derivative
CA2618112A1 (en)	2005-08-10	2007-02-15	Banyu Pharmaceutical Co., Ltd.	Pyridone compound
BRPI0614649A2 (pt)	2005-08-11	2011-04-12	Amylin Pharmaceuticals Inc	polipeptìdeos hìbridos com propriedades selecionáveis
AU2006279680B2 (en)	2005-08-11	2012-12-06	Amylin Pharmaceuticals, Llc	Hybrid polypeptides with selectable properties
WO2007024004A1 (ja)	2005-08-24	2007-03-01	Banyu Pharmaceutical Co., Ltd.	フェニルピリドン誘導体
AU2006288153A1 (en)	2005-09-07	2007-03-15	Msd K.K.	Bicyclic aromatic substituted pyridone derivative
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
RU2008119687A (ru)	2005-10-21	2009-11-27	Новартис АГ (CH)	Комбинации органических соединений
CA2627139A1 (en)	2005-10-27	2007-05-03	Banyu Pharmaceutical Co., Ltd.	Novel benzoxathiin derivative
ES2381205T3 (es)	2005-11-10	2012-05-24	Msd K.K.	Derivado espiro aza-sustituido
BRPI0706623A2 (pt)	2006-01-18	2011-04-12	Schering Corp	moduladores de receptor canabinóide
US8247442B2 (en)	2006-03-29	2012-08-21	Purdue Pharma L.P.	Benzenesulfonamide compounds and their use
TW200812963A (en)	2006-04-13	2008-03-16	Euro Celtique Sa	Benzenesulfonamide compounds and the use thereof
TW200815353A (en)	2006-04-13	2008-04-01	Euro Celtique Sa	Benzenesulfonamide compounds and their use
CA2661371A1 (en) *	2006-08-30	2008-03-06	Biovitrum Ab (Publ)	Pyrimidine compounds for treating gpr119 related disorders
WO2008026564A1 (en) *	2006-08-30	2008-03-06	Shionogi & Co., Ltd.	Urea derivative
US8173629B2 (en)	2006-09-22	2012-05-08	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
WO2008047544A1 (en)	2006-09-28	2008-04-24	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
CN101657471B (zh) *	2006-12-06	2013-07-03	史密丝克莱恩比彻姆公司	二环化合物及其作为抗糖尿病药的用途
JP5319518B2 (ja)	2007-04-02	2013-10-16	Ｍｓｄ株式会社	インドールジオン誘導体
US8399486B2 (en)	2007-04-09	2013-03-19	Purdue Pharma L.P.	Benzenesulfonyl compounds and the use thereof
US20100197564A1 (en) *	2007-04-19	2010-08-05	Schering Corporation	Diaryl morpholines as cb1 modulators
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es)	2007-06-04	2010-02-15	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
EP2548874A3 (de) *	2007-06-28	2013-05-15	Intervet International B.V.	Substituierte Piperazine als CB1-Antagonisten
US20100286160A1 (en) *	2007-06-28	2010-11-11	Intervet Inc.	Substituted piperazines as cb1 antagonists
US8765736B2 (en)	2007-09-28	2014-07-01	Purdue Pharma L.P.	Benzenesulfonamide compounds and the use thereof
JPWO2009110510A1 (ja)	2008-03-06	2011-07-14	Ｍｓｄ株式会社	アルキルアミノピリジン誘導体
US20110015198A1 (en)	2008-03-28	2011-01-20	Banyu Pharmaceutical Co., Inc.	Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP2146210A1 (de)	2008-04-07	2010-01-20	Arena Pharmaceuticals, Inc.	Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
EP2810951B1 (de)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
JPWO2009154132A1 (ja)	2008-06-19	2011-12-01	Ｍｓｄ株式会社	スピロジアミン−ジアリールケトオキシム誘導体
CA2730603C (en)	2008-07-16	2019-09-24	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2010013595A1 (ja)	2008-07-30	2012-01-12	Ｍｓｄ株式会社	５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
EP2348857B1 (de)	2008-10-22	2016-02-24	Merck Sharp & Dohme Corp.	Neue cyclische benzimidazolderivate als antidiabetika
EP2350010B1 (de)	2008-10-30	2014-03-26	Merck Sharp & Dohme Corp.	Isonikotinamide als orexinrezeptorantagonisten
JP5557845B2 (ja)	2008-10-31	2014-07-23	メルク・シャープ・アンド・ドーム・コーポレーション	糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
AU2011218830B2 (en)	2010-02-25	2014-07-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
MX348131B (es)	2011-02-25	2017-05-26	Merck Sharp & Dohme	Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
CN102718703B (zh) *	2011-03-31	2016-09-14	中国医学科学院药物研究所	Gk和ppar双重激动活性的含有二甲基的芳基脲类衍生物
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2014022528A1 (en)	2012-08-02	2014-02-06	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
CN103910694B (zh) *	2012-12-29	2016-08-24	广东东阳光药业有限公司	一种2-芳基腈噻唑衍生物的制备方法
WO2014130608A1 (en)	2013-02-22	2014-08-28	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EA201592263A1 (ru)	2013-06-05	2016-05-31	Синерджи Фармасьютикалз, Инк.	Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
EP3186242B1 (de)	2014-08-29	2021-10-06	Tes Pharma S.r.l.	Inhibitoren von alpha-amino-beta-carboxymuconsäure semialdehyd-decarboxylase
WO2017114377A1 (zh) *	2015-12-29	2017-07-06	四川海思科制药有限公司	一种苯基杂环衍生物及其在医药上的用途
AU2017342083A1 (en)	2016-10-14	2019-04-11	Tes Pharma S.R.L.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
EP3558298B1 (de)	2016-12-20	2026-03-11	Merck Sharp & Dohme LLC	Antidiabetische spirochromanverbindungen
EP3793552B1 (de) *	2018-05-15	2023-07-12	The Scripps Research Institute	Abhd12-inhibitoren und verfahren zur herstellung und verwendung davon
AR117122A1 (es)	2018-11-20	2021-07-14	Tes Pharma S R L	INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
TW202045476A (zh)	2019-02-13	2020-12-16	美商默沙東藥廠	5-烷基吡咯啶食慾素受體促效劑
EP3923933A4 (de)	2019-02-13	2022-08-17	Merck Sharp & Dohme Corp.	Pyrrolidinorexin-rezeptor-agonisten
WO2021026047A1 (en)	2019-08-08	2021-02-11	Merck Sharp & Dohme Corp.	Heteroaryl pyrrolidine and piperidine orexin receptor agonists
MX2023001840A (es)	2020-08-18	2023-03-13	Merck Sharp & Dohme Llc	Agonistas de bicicloheptano pirrolidina de los receptores de orexina.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2928485A1 (de) *	1979-07-14	1981-01-29	Bayer Ag	Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4623662A (en) *	1985-05-23	1986-11-18	American Cyanamid Company	Antiatherosclerotic ureas and thioureas
US5602024A (en)	1994-12-02	1997-02-11	Synaptic Pharmaceutical Corporation	DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US6043246A (en) *	1996-12-03	2000-03-28	Banyu Pharmaceutical Co., Ltd.	Urea derivatives
AR016817A1 (es) *	1997-08-14	2001-08-01	Smithkline Beecham Plc	Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
ES2154253T3 (es) *	1997-12-22	2012-01-27	Bayer Healthcare Llc	Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas.
WO2000027845A1 (en)	1998-11-10	2000-05-18	Merck & Co., Inc.	Spiro-indolines as y5 receptor antagonists
WO2000063171A1 (en) *	1999-04-20	2000-10-26	Meiji Seika Kaisha, Ltd.	Tricyclic compounds
TWI279402B (en)	1999-08-20	2007-04-21	Banyu Pharma Co Ltd	Spiro compounds having NPY antagonistic activities and agents containing the same
WO2001037826A1 (en)	1999-11-26	2001-05-31	Shionogi & Co., Ltd.	Npyy5 antagonists

2001
- 2001-12-17 DE DE60136562T patent/DE60136562D1/de not_active Expired - Lifetime
- 2001-12-17 SG SG200503925-0A patent/SG138463A1/en unknown
- 2001-12-17 ES ES01985069T patent/ES2316486T3/es not_active Expired - Lifetime
- 2001-12-17 BR BR0116379-5A patent/BR0116379A/pt not_active Application Discontinuation
- 2001-12-17 MX MXPA03005745A patent/MXPA03005745A/es active IP Right Grant
- 2001-12-17 JP JP2002550988A patent/JP4226326B2/ja not_active Expired - Fee Related
- 2001-12-17 IL IL15615701A patent/IL156157A0/xx unknown
- 2001-12-17 AU AU3405602A patent/AU3405602A/xx active Pending
- 2001-12-17 KR KR10-2003-7008229A patent/KR20030061458A/ko not_active Ceased
- 2001-12-17 NZ NZ526174A patent/NZ526174A/xx unknown
- 2001-12-17 WO PCT/US2001/049302 patent/WO2002049648A1/en not_active Ceased
- 2001-12-17 CN CNA2006100050504A patent/CN1807426A/zh active Pending
- 2001-12-17 AU AU2002234056A patent/AU2002234056B2/en not_active Ceased
- 2001-12-17 EP EP01985069A patent/EP1343503B1/de not_active Expired - Lifetime
- 2001-12-17 CA CA2432809A patent/CA2432809C/en not_active Expired - Fee Related
- 2001-12-17 HU HU0303339A patent/HUP0303339A3/hu unknown
- 2001-12-17 CN CNA018211720A patent/CN1482912A/zh active Pending
- 2001-12-17 HK HK03106723.8A patent/HK1054333A1/zh unknown
- 2001-12-17 AR ARP010105841A patent/AR035520A1/es not_active Application Discontinuation
- 2001-12-17 AT AT01985069T patent/ATE413880T1/de not_active IP Right Cessation
- 2001-12-18 PE PE2001001267A patent/PE20020761A1/es not_active Application Discontinuation
- 2001-12-18 US US10/026,651 patent/US6982267B2/en not_active Expired - Lifetime
2003
- 2003-06-03 ZA ZA200304348A patent/ZA200304348B/en unknown
- 2003-06-20 NO NO20032861A patent/NO20032861L/no unknown

Also Published As

Publication number	Publication date
CN1807426A (zh)	2006-07-26
ATE413880T1 (de)	2008-11-15
WO2002049648A1 (en)	2002-06-27
AR035520A1 (es)	2004-06-02
CA2432809C (en)	2010-11-30
NZ526174A (en)	2004-12-24
HUP0303339A2 (hu)	2004-01-28
DE60136562D1 (de)	2008-12-24
US6982267B2 (en)	2006-01-03
JP4226326B2 (ja)	2009-02-18
KR20030061458A (ko)	2003-07-18
JP2004516267A (ja)	2004-06-03
HK1054333A1 (zh)	2003-11-28
SG138463A1 (en)	2008-01-28
EP1343503A4 (de)	2004-03-17
CN1482912A (zh)	2004-03-17
BR0116379A (pt)	2003-09-30
MXPA03005745A (es)	2003-09-05
ES2316486T3 (es)	2009-04-16
EP1343503B1 (de)	2008-11-12
HUP0303339A3 (en)	2004-04-28
IL156157A0 (en)	2003-12-23
PE20020761A1 (es)	2002-08-22
US20030055062A1 (en)	2003-03-20
EP1343503A1 (de)	2003-09-17
AU3405602A (en)	2002-07-01
NO20032861D0 (no)	2003-06-20
CA2432809A1 (en)	2002-06-27
ZA200304348B (en)	2004-09-09
AU2002234056B2 (en)	2005-04-07

Publication	Publication Date	Title
HK1054333A1 (zh)	2003-11-28	杂芳基脲神经肽yy5受体拮抗剂
DK1716152T3 (da)	2008-11-03	Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
MXPA04000707A (es)	2004-04-20	Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
WO2003028641A3 (en)	2003-08-28	Mch receptor antagonists
WO2006044504A8 (en)	2006-06-08	Cgrp receptor antagonists
DE60224404D1 (de)	2008-02-14	Substiuierte piperidine als melanocortinrezeptor-modulatoren
DK1076644T3 (da)	2004-08-30	N-Substituerede aminotetraliner som ligander for neutopeptid Y Y5-receptoren, der er nyttig til behandling af fedme og andre lidelser
DE60335869D1 (de)	2011-03-10	1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
DE602005020655D1 (de)	2010-05-27	Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
DE60131967D1 (de)	2008-01-31	Nr1h4-kern-rezeptor-bindende verbindungen
NO20045120L (no)	2004-12-07	Triazolderivater som takykininreseptorantagonister
WO2004092166A3 (en)	2005-01-20	Cgrp receptor antagonists
NO20063599L (no)	2006-10-27	Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20075781L (no)	2008-02-05	Diarylsulfone-sulfonamider og deres anvendelse
WO2004091514A3 (en)	2005-09-15	Cgrp receptor antagonists
DE60229530D1 (de)	2008-12-04	Substituierte piperazine als modulatoren des melanocortinrezeptors
SE0302760D0 (sv)	2003-10-20	New compounds
NO20063928L (no)	2006-10-31	Substituerte kinolinforbindelser
NO20060195L (no)	2006-03-13	Kinolylamidderivater som CCR-5-antagonister
ATE484505T1 (de)	2010-10-15	5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
ATE399770T1 (de)	2008-07-15	Tachykininrezeptorantagonisten
NO20050921L (no)	2005-04-28	Nye fysiologisk aktive substanser
BR0206595A (pt)	2004-07-13	Composto, composição farmacêutica, e uso de um composto
WO2007079163A3 (en)	2007-08-30	Prokineticin 1 receptor antagonists
WO2006047196A3 (en)	2006-10-05	Cgrp receptor antagonists